Dr Reddy's Laboratories gains 5% on posting Q3 results; brokerages divided

In Q3, Dr Reddy's Laboratories reported a 14 per cent year-on-year (Y-o-Y) decline in consolidated net profit to ₹1,210 crore, as compared to ₹1,413 crore a year ago

Shares of Dr Reddy’s Laboratories jumped 5.3 per cent on Thursday to ₹1,217 apiece, making it the top gainer in the Nifty 50 and the BSE 100 indices. In comparison, the Nifty 50 was up 0.53 per cent at 25,289.

 

The buying on the counter came after the company reported its results for the third quarter (October-December) of 2025-26 (Q3FY26) on Wednesday, after market hours. Analysts are broadly constructive on Dr Reddy's Labs’ medium-term prospects despite Q3FY26 margin pressure, with views split on near-term risks.

 

In Q3FY26, Dr Reddy’s Labs reported a 14 per cent year-on-year (Y-o-Y) decline in consolidated net profit to ₹1,210 crore, as compared to ₹1,413 crore a year ago. The firm’s revenue from operations rose to ₹8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from ₹8,357 crore in Q3FY25.

 

 

The company’s earnings before interest, taxes, depreciation, and amortisation (Ebitda) stood at ₹2,049 crore, as compared to ₹2,298 crore a year ago.  ALSO READ | Bajaj Consumer Care stock soars 11% on bullish calls from analysts; check target

 

Motilal Oswal Research said Dr Reddy’s Labs delivered a better-than-expected Q3FY26, with strong execution in India, Europe and Russia, and favourable currency movement more than offsetting the drag due to weaker contribution from the generic version of cancer drug Revlimid, resulting in an earnings beat.

 

The brokerage cut its FY26 estimates by 4 per cent to factor in a delay in the launch of diabetes/weight control drug semaglutide in Canada, but raised FY27 estimates by 6 per cent on better growth prospects across India, Europe and Russia. It has a “neutral” rating, with a target price of ₹1,220.

 

JM Financial believes margin pressure reflects ongoing headwinds in the US market. However, it sees strong growth excluding the US market, a rich filing pipeline, and upcoming semaglutide launches providing medium-term earnings visibility, with the worst largely factored into current valuations. In Q3FY26, the company’s operating profit margins contracted sharply by 579 basis points (bps) Y-o-Y, reflecting lower Revlimid sales, an adverse product mix, and sustained pricing pressure, although overall profitability still beat Street expectations. It has raised its target price to ₹1,545 from ₹1,522.  ALSO READ | Zomato share price up 6%; here's how analysts view Eternal Q3 results, leadership transition

 

Elara Capital estimates one-off Revlimid sales of $50-60 million in Q3FY26, and believes that the opportunity window has closed. North America's business was down Y-o-Y and quarter-on-quarter (Q-o-Q), as expected. All the other businesses performed in line or posted a beat. India's business grew 19 per cent Y o-Y, and the company expects it to sustain above 15 per cent, which is a major positive highlight. The brokerage maintained its FY26-FY28 core earnings estimates broadly. It has a “buy” rating target price of ₹1,588.

 

Emkay Research said Dr Reddy’s Q3FY26 margin performance was in line with its expectations, and about 100 bps ahead of Street estimates on an adjusted basis (excluding one-offs). The brokerage noted that a higher adjusted gross margin was offset by higher selling, general, and administrative spending. While the brokerage sees limited room for further negative pipeline surprises, its base case is that FY28 earnings per share (EPS) will still be lower than FY25 earnings. It marginally raised earnings estimates after tweaking domestic growth and forex assumptions, and rolling forward to December 2027 earnings. The brokerage has a “reduce” rating, though it has raised its target price from ₹1,000 to ₹1,200. 

 

Disclaimer: View and outlook shared belong to the respective brokerages/analysts and are not endorsed by Business Standard. Readers discretion is advised.